Epigenomics AG

EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG announces changes in its Executive Management Board

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information/molecular diagnostics

25.09.2012

Berlin, Germany, September 25, 2012 - The Supervisory Board of Epigenomics AG
(ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that
Mr. Nygaard will leave the Executive Management Board of the company effective
30 September 2012.

The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board
member of the company and this capacity also takes over the responsibility of
acting CEO of Epigenomics, effective 1 October 2012. Dr. Uwe Staub, currently
SVP R&D was promoted to COO and was granted "Prokura" (power of attorney). His
duties will be expanded by the responsibility for medical affairs and customer
support.

The Supervisory Board thanks Mr. Nygaard for his commitment and contributions to
Epigenomics over the last years.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR 
Epigenomics AG 
Phone: +49 (0) 30 24345 386 
ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of Epigenomics AG to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication as of
this date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: